Key result
Liquid biopsy biomarkers lack FDA clearance for stroke diagnosis within the 4.5-hour therapeutic window.
Answers are grounded in this paper and cite their sources.
INTRODUCTION: There is a short time window (4.5 h) for the effective treatment of acute ischemic stroke (AIS), which uses recombinant tissue plasminogen activator (rt-PA). Unfortunately, this short therapeutic timeframe is a contributing factor to the relatively small number of patients (~7%) that receive rt-PA. While neuroimaging is the major diagnostic for AIS, more timely decisions could be made using a molecular diagnostic. AREAS COVERED: . liquid biopsy) biomarkers, for diagnosing stroke to allow for precision decisions on managing stroke in a timely manner. Both protein and nucleic acid molecular biomarkers are reviewed. In particular, mRNA markers are discussed for AIS and hemorrhagic stroke diagnosis sourced from both cells and extracellular vesicles. EXPERT OPINION: While there are a plethora of molecular markers for stroke diagnosis that have been reported, they have yet to be FDA-cleared. Possible reasons include the inability for these markers to appear in sufficient quantities for highly sensitive clinical decisions within the rt-PA therapeutic time.
No takes yet. Share an insight, caveat, or question.
Wijerathne et al. (2020) conducted a review in Acute ischemic stroke and hemorrhagic stroke. Liquid biopsy biomarkers (protein and nucleic acid/mRNA markers) vs. Neuroimaging was evaluated on Stroke diagnosis within the 4.5 h rt-PA therapeutic window. Liquid biopsy biomarkers for stroke are not yet FDA-cleared, potentially due to insufficient marker quantities within the 4.5-hour rt-PA therapeutic window.
Synapse has enriched 10 related papers. Consider them for comparative context: